The University College London gene therapy spinout has completed a series B round backed by the institution's UCL Technology Fund.
Orchard Therapeutics, a UK-based genetics spinout from University College London (UCL), closed an oversubscribed $110m series B round today with contributions from UCL and Singaporean state-owned investment firm Temasek.
The round was co-led by investment firm Baillie Gifford and venture capital fund Ori Capital. UCL took part through UCL Technology Fund, which was established to invest in commercial opportunities derived from the university’s research.
F-Prime Capital, a branch of financial services group Fidelity International, also contributed to the round, as…
